This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Our Team
https://www.zylorion.com/wp-content/uploads/2021/12/peter-silverstone.png
Dr. Peter Silverstone
Chief Executive Officer and Director
Dr. Peter Silverstone
Chief Executive Officer and Director
Dr. Silverstone has a 35-year background in brain and pharmaceutical research. Dr. Silverstone has highly relevant expertise in international drug and IP development, digital mental health, regulatory matters, and has been involved in multiple health related start-up companies. Dr. Silverstone previously served as the Senior Vice President, Medical and Scientific Affairs of Biovail, one of Canada’s largest publicly traded pharmaceutical companies with annual revenue in excess of a billion dollars, prior to its merger with Valeant Pharmaceutical International. Dr. Silverstone is currently the Interim Chair of the Department of Psychiatry at the University of Alberta. Dr. Silverstone received his MD at the University of London and spent three years as a research fellow at the University of Oxford. Dr. Silverstone’s research achievements have won several awards and he has published over 120 peer-reviewed articles. Dr. Silverstone is the author of the The Promise of Psychedelics, available here or wherever you buy your books.
https://www.zylorion.com/wp-content/uploads/2021/12/tracy-hillier.png
Dr. Tracey Hillier
Chief Clinical Officer
Dr. Tracey Hillier
Chief Clinical Officer
Dr. Hillier is a proud member of the Qalipu Mi’kmaq First Nation and spent 20 years in the Canadian Armed Forces as a physician. During this time Dr. Hillier gained extensive experience in working with patients with PTSD, Depression, Anxiety, and Addictions, the four key areas of clinical focus for Zylorion. Additionally, Dr. Hillier gained expertise in international logistics in the medical field, working in multiple countries in a wide variety of roles. She trained at a master’s level in clinical trial methodology, and also at the Master’s level in Education. Dr. Hillier has led the development of a complex computerized medical training system, and oversaw its successful implementation, in a world- renowned university. Her most recent role was as Director and Executive Dean, Alberta Institute Wenzhou Medical University, an international collaborative start-up between the University of Alberta and a leading Chinese medical facility.
https://www.zylorion.com/wp-content/uploads/2021/12/louise-duchesne.png
Louise M. Duchesne
Chief Financial Officer
Louise M. Duchesne, CPA, CA
Chief Financial Officer
Ms. Duchesne is co-founder and Managing Director of Lightyear Capital Inc., a privately held full-service, IIROC member, investment dealer. Ms. Duchesne has over 30-years of capital markets, finance, accounting, tax, regulatory compliance, and investment industry experience. Prior to co-founding Lightyear, Ms. Duchesne was the Chief Financial Officer and Director of an independent investment dealer. Ms. Duchesne holds a Bachelor of Commerce from McGill University and a CPA, CA designation.
https://www.zylorion.com/wp-content/uploads/2021/12/scott-phillips.png
Scott Phillips
Chief Operating Officer
Scott Phillips, MBA, CPA, CMA
Chief Operating Officer
Mr. Phillips has over 20-years leadership experience in operations across several different industries. Most recently, Mr. Phillips was Assistant Chair, for the Department of Psychiatry at the University of Alberta where he worked directly with mental health education and service delivery. Prior to that, Mr. Phillips led the logistics network for Canada’s third largest private lab, with a team of over 65 employees and contracts covering Western Canada. Mr. Phillips has led multi million-dollar start-ups with focus on both the domestic and international markets, specifically in the technology and fabrication space. Mr. Phillips gained his MBA from Cornell University and maintains a CPA, CMA designation, as well as a PMP designation. In 2019, Mr. Phillips was named one of the Top 40 under 40 in Edmonton, Alberta.
https://www.zylorion.com/wp-content/uploads/2021/12/scott-clarke.png
Scott Clarke
Corporate Secretary
Scott Clarke, B. Comm (Hons), LLB
Corporate Secretary
Mr. Clarke is a senior partner with Blake, Cassels & Graydon LLP, with 24-years experience focused on mergers and acquisitions, power projects, corporate finance, private equity and governance matters (including ESG). Mr. Clarke’s diverse public and private company client base spans life sciences, technology, power (with a focus on alternative energy), oil and gas services and exploration. Mr. Clarke is recognized as a leading lawyer in the Legal 500 Canada, Chambers Canada: Canada’s Leading Lawyers for Business, the Best Lawyers in Canada, the Canadian Legal Lexpert Directory, and Acritas Stars. Mr. Clarke is also a member of the Securities Advisory Committee of the Alberta Securities Commission.
https://www.zylorion.com/wp-content/uploads/2021/12/murray-weimer.png
Murray Weimer
Chairman and Director
Murray Weimer
Chairman and Director
Mr. Weimer is co-founder and Managing Director of Lightyear Capital Inc. (“Lightyear”), a privately held full-service, IIROC member, investment dealer. Mr. Weimer oversees all aspects of Lightyear’s investment banking initiatives and Lightyear’s merchant banking division. Over Mr. Weimer’s 25-year career he has supported the start up and growth of multiple companies in a diverse range of business lines and has executed on numerous M&A, valuation, equity and debt financing assignments. As Chairman of PsiloTec, Mr. Weimer is actively involved in all aspects of PsiloTec’s business strategy along with providing leadership on executing PsiloTec’s capital markets strategy. Mr. Weimer holds a Bachelor of Commerce from the University of Saskatchewan and a CPA, CA designation.
https://www.zylorion.com/wp-content/uploads/2021/12/james-mich.png
Jim Mish
Director
Jim Mish
Director
Mr. Mish is currently the CEO of 22nd Century Group, Inc., a leading plant biotechnology company focused on technologies that alter the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene editing and modern plant breeding. Mr. Mish has an outstanding 35-year track record of delivering profitable growth at both privately held and publicly traded companies with a focus on pharmaceutical and consumer products. Prior thereto, Mr. Mish served as President and CEO of Purisys, a synthetic cannabinoid API, ingredients and solutions provider to pharmaceutical and consumer products companies, and Noramco, a global leader in the production of controlled substances for the pharmaceutical industry. Mr. Mish is a graduate from the Pennsylvania State University in Chemistry and The University of Pennsylvania, Wharton School of Business.
https://www.zylorion.com/wp-content/uploads/2021/12/jeroen-tas-full.png
Jeroen Tas
Director
Jeroen Tas
Strategic Advisor & Board Observer
Mr. Tas is an innovation leader who applies his entrepreneurship, experience in large scale digital transformation and expertise in information technology (Cloud, AI, IoT, cyber security) to transform and grow businesses. In Mr. Tas’ 10-year tenure at Koninklijke Philips N.V. (NYSE:PHG;AMS:PHIA), in the role of Chief Innovation and Strategy Officer, Mr. Tas was instrumental in the transition of Philips to a customer-centric, digital health tech solutions company. Before joining Philips, Mr. Tas co-founded and served as President, COO and Vice-Chairman of the Board for Mphasis, a technology solutions company focused on services for the financial industry, which was acquired by HP (EDS) in 2006. Mr. Tas is the 2004 winner of the E&Y Entrepreneur of the Year Award in the Information Technology category for the New York region. Mr. Tas was also the recipient of the 2013 Dutch CIO of the year award, NASSCOM 2014 Global CIO award, the World Innovation Congress 2014 CIO Leadership award, the CIONet 2014 European CIO award, the IT Executive 2014 award, and the Accenture 2015 Innovator of the Year award. Mr. Tas is a native of the Netherlands and holds a Master’s degree in Computer Science and Business Administration from the Vrije University, Amsterdam.
https://www.zylorion.com/wp-content/uploads/2021/12/peter-silverstone.png
Dr. Peter Silverstone
Chief Executive Officer and Director
Dr. Peter Silverstone
Chief Executive Officer and Director
Dr. Silverstone has a 35-year background in brain and pharmaceutical research. Dr. Silverstone has highly relevant expertise in international drug and IP development, digital mental health, regulatory matters, and has been involved in multiple health related start-up companies. Dr. Silverstone previously served as the Senior Vice President, Medical and Scientific Affairs of Biovail, one of Canada’s largest publicly traded pharmaceutical companies with annual revenue in excess of a billion dollars, prior to its merger with Valeant Pharmaceutical International. Dr. Silverstone is currently the Interim Chair of the Department of Psychiatry at the University of Alberta. Dr. Silverstone received his MD at the University of London and spent three years as a research fellow at the University of Oxford. Dr. Silverstone’s research achievements have won several awards and he has published over 120 peer-reviewed articles.